We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
BioLineRx announced it met with the U.S. Food and Drug Administration (FDA) and gained clarity on the development program and the design of a Phase 3 pivotal study for BL-8040 as a novel stem cell mobilization treatment for autologous bone-marrow transpla